Technion Research and Development Foundation

CAPS Medical Ltd is a medical device company based in Netanya, Israel, dedicated to developing and commercializing a novel cancer treatment technology using non-thermal atmospheric plasma. Founded in 2018, CAPS Medical aims to provide a minimally invasive solution for treating solid tumors while preserving surrounding healthy tissue. The company emerged from a collaboration between the Technion’s Plasma Lab and Rambam Medical Center’s Cancer Lab, driven by extensive scientific research to address unmet needs in the oncology therapeutics market. Through its innovative approach, CAPS Medical seeks to enhance cancer treatment effectiveness and safety, targeting a wide range of solid tumors.

Amplio is the first and only Impact Platform for Special Education. We are on a mission to help students with special learning needs reach their full potential. The Amplio Platform including research and evidence-based curricula and programs is designed to deliver intensive, rigorous instruction to prepare students for success, both academically and in their everyday lives. Our solutions are developed in conjunction with parents and a world- class advisory council, academics, and school administrators with expertise in special populations. Tens of thousands of students have received services and interventions using the Amplio platform since the solution was launched in 2019.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.

Correlsense is a developer of application performance management software that aids businesses in achieving IT reliability by monitoring and managing application performance. Founded in 2005 and privately held, Correlsense's flagship product, SharePath, provides comprehensive visibility into data center operations by tracking every transaction as it moves through the system. This capability allows businesses to quickly identify and resolve issues related to application performance, including crashes and slowdowns. SharePath is designed for ease of deployment and maintenance, making it suitable for organizations of all sizes. The software enhances the end-user experience, mitigates risks associated with new service rollouts and data center migrations, facilitates chargebacks for IT resources, and improves capacity planning. Additionally, Correlsense offers an Express edition of SharePath, which is a free enterprise-class software tool that measures the end-user experience for both cloud-based and on-premise applications.

DigiFlex Ltd. is a manufacturer of innovative inkjet printing systems, specializing in the production of photopolymer flexographic, letterpress, dry-offset, and rotary silk screen printing plates. Established in 2005 and based in Kefar Sava, Israel, the company offers an inkjet-based computer-to-plate (CtP) solution that enhances the quality of analog printing plates while streamlining the production process. DigiFlex’s technology eliminates the need for traditional film and chemical processing, allowing users to manage the entire plate-making process in-house. This capability not only improves efficiency but also reduces costs for narrow web application printers. DigiFlex’s products are distributed across Europe, North America, the Far East, and other international markets. As of late 2017, DigiFlex operates as a subsidiary of P.V. Nano Cell Ltd.

DigiFlex Ltd. is a manufacturer of innovative inkjet printing systems, specializing in the production of photopolymer flexographic, letterpress, dry-offset, and rotary silk screen printing plates. Established in 2005 and based in Kefar Sava, Israel, the company offers an inkjet-based computer-to-plate (CtP) solution that enhances the quality of analog printing plates while streamlining the production process. DigiFlex’s technology eliminates the need for traditional film and chemical processing, allowing users to manage the entire plate-making process in-house. This capability not only improves efficiency but also reduces costs for narrow web application printers. DigiFlex’s products are distributed across Europe, North America, the Far East, and other international markets. As of late 2017, DigiFlex operates as a subsidiary of P.V. Nano Cell Ltd.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.